The Mouse Stent Model is a fast, predictive model of how a new therapeutic will affect the diseased human artery when implanted as part of a drug-eluting stent. This high-throughput system provides the ideal method to screen therapeutic leads advancing from pharmaceutical and biotech companies as well as university laboratories. Many of these have not had ready access to the specialized tools or expertise needed to evaluate the potential value of their leads for interventional cardiology applications.
The market release coincides with BIO, because the biotech and pharmaceutical companies participating in the international meeting this week in San Diego, CA represent ideal users of the new testing model. NanoInterventions can assist BIO community stakeholders assess the potential value of their therapeutic discoveries for device-delivered treatments and chart a path for further development, thereby enhancing the value of their intellectual property and creating a justification for the later, more costly development program required to advance a cardiovascular combination device toward regulatory approval -- and potentially licensing rights to or selling the newly enhanced asset.
The wide-ranging expertise within the Minnesota-based partnership can
guide combination drug/devices from concept through clinical trials and
regulatory approval. The Integra Group anchors the development operations
with its extensive experience in early stage cardiovascular research and
managing complex development programs, beginning with non-human testing and
extending to approval-pathway clinical trials. Nanocopoeia, an innovator in
producing nanoengineered drug coatings for medical devices, incorporates
the candidate drugs or biologics into the mini-stent coating. Coating the
mini-stent is a s
Copyright©2008 PR Newswire.
All rights reserved